Strategic partnerships Leverage Cognito’s expanding Brain Health Collaboratories with Ochsner Health and Rhode Island Life Science Hub to co-create clinical programs, pilot at-home Spectris deployments, and scale access through health systems and life sciences ecosystems.

Clinical progression Target health systems and payers with the company’s FDA Breakthrough Device Designation and Phase II/IIb data showing slowed cognitive decline and reduced brain atrophy, positioning Spectris as a leading neuromodulation therapy in Alzheimer’s disease.

Home treatment potential Position Spectris as an at‑home neuromodulation option through partnerships with regional networks like Ochsner, expanding telehealth integration, remote monitoring, and device distribution to increase patient reach and adherence.

Research enablement Capitalize on biomarker insights from AAIC presentations to build payer and research collaborations focused on mechanistic evidence, lipid transport and myelination pathways, and real-world outcomes data.

Commercial scale Capitalize on a strong funding base and multi‑regional collaborations to pursue large‑scale deployments, direct hospital contracts, and channel partnerships, supported by a mid‑sized company profile and a revenue range indicative of growth opportunities.